Вы находитесь на странице: 1из 4

1. US Renal Data System. National Institute of Diabetes and Digestive and Kidney Disease.

USRDS 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United
States. Bethesda, Md: National Institutes of Health,; 2011. [Full Text].

2. Zuccalà A, Zucchelli P. Is nephroangiosclerosis a hypertension-induced nephropathy?.


Contrib Nephrol. 1996. 119:110-4. [Medline].

3. Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, et al. The association
between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med.
2010 May 4. 152(9):561-7. [Medline]. [Full Text].

4. Tracy RE, Ishii T. What is 'nephrosclerosis'? lessons from the US, Japan, and Mexico.
Nephrol Dial Transplant. 2000 Sep. 15(9):1357-66. [Medline].

5. Wang G, Lai FM, Kwan BC, et al. Podocyte loss in human hypertensive nephrosclerosis.
Am J Hypertens. 2009 Mar. 22(3):300-6. [Medline].

6. Wang G, Kwan BC, Lai FM, et al. Intrarenal expression of miRNAs in patients with
hypertensive nephrosclerosis. Am J Hypertens. 2010 Jan. 23(1):78-84. [Medline].

7. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is
associated with nondiabetic end-stage renal disease in African Americans. Nat Genet.
2008 Oct. 40(10):1185-92. [Medline]. [Full Text].

8. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is
associated with nondiabetic end-stage renal disease in African Americans. Nat Genet.
2008 Oct. 40(10):1185-92. [Medline]. [Full Text].

9. Freedman BI, Sedor JR. Intensive blood-pressure control in hypertensive chronic kidney
disease. N Engl J Med. 2010 Dec 23. 363(26):2565; author reply 2565-6. [Medline].

10. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al.
Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
Science. 2010 Aug 13. 329(5993):841-5. [Medline]. [Full Text].

11. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al.
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet.
2008 Oct. 40(10):1175-84. [Medline]. [Full Text].

12. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive
blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep
2. 363(10):918-29. [Medline].

13. Freedman BI, Murea M. Target organ damage in African American hypertension: role of
APOL1. Curr Hypertens Rep. 2012 Feb. 14(1):21-8. [Medline]. [Full Text].

14. Fung MM, Chen Y, Lipkowitz MS, et al. Adrenergic beta-1 receptor genetic variation
predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol Dial
Transplant. 2009 Dec. 24(12):3677-86. [Medline]. [Full Text].
15. Moutzouris DA, Herlitz L, Appel GB, et al. Renal biopsy in the very elderly. Clin J Am
Soc Nephrol. 2009 Jun. 4(6):1073-82. [Medline]. [Full Text].

16. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal
failure. Ann Intern Med. 1993 May 1. 118(9):712-9. [Medline].

17. Appel RG, Bleyer AJ, Reavis S, et al. Renovascular disease in older patients beginning
renal replacement therapy. Kidney Int. 1995 Jul. 48(1):171-6. [Medline].

18. Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the
elderly: a population-based study. J Vasc Surg. 2002 Sep. 36(3):443-51. [Medline].

19. Pillay WR, Kan YM, Crinnion JN, et al. Prospective multicentre study of the natural
history of atherosclerotic renal artery stenosis in patients with peripheral vascular
disease. Br J Surg. 2002 Jun. 89(6):737-40. [Medline].

20. Olin JW. Atherosclerotic renal artery disease. Cardiol Clin. 2002 Nov. 20(4):547-62, vi.
[Medline].

21. US Food and Drug Administration. Information for Healthcare Professionals.


Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm.

22. Dorros G, Jaff M, Mathiak L, et al. Multicenter Palmaz stent renal artery stenosis
revascularization registry report: four-year follow-up of 1,058 successful patients.
Catheter Cardiovasc Interv. 2002 Feb. 55(2):182-8. [Medline].

23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh
report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension. 2003 Dec. 42(6):1206-52. [Medline].

24. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy.
Circulation. 2005 Aug 30. 112(9):1362-74. [Medline].

25. Textor SC. Atherosclerotic renal artery stenosis: overtreated but underrated?. J Am Soc
Nephrol. 2008 Apr. 19(4):656-9. [Medline].

26. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am


Soc Nephrol. 1998 Jan. 9(1):133-42. [Medline].

27. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization
versus medical therapy for renal-artery stenosis. N Engl J Med. 2009 Nov 12.
361(20):1953-62. [Medline].

28. Innes A, Johnston PA, Morgan AG, et al. Clinical features of benign hypertensive
nephrosclerosis at time of renal biopsy. Q J Med. 1993 Apr. 86(4):271-5. [Medline].

29. Harvey JM, Howie AJ, Lee SJ, et al. Renal biopsy findings in hypertensive patients with
proteinuria. Lancet. 1992 Dec 12. 340(8833):1435-6. [Medline].
30. Freedman BI, Iskander SS, Buckalew VM Jr, et al. Renal biopsy findings in presumed
hypertensive nephrosclerosis. Am J Nephrol. 1994. 14(2):90-4. [Medline].

31. Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive
nephrosclerosis in African Americans: a report from the African American Study of
Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997 Jan.
51(1):244-52. [Medline].

32. Beevers DG, Lip GY. Does non-malignant essential hypertension cause renal damage? A
clinician's view. J Hum Hypertens. 1996 Oct. 10(10):695-9. [Medline].

33. Madhavan S, Stockwell D, Cohen H, et al. Renal function during antihypertensive


treatment. Lancet. 1995 Mar 25. 345(8952):749-51. [Medline].

34. Zucchelli P, Zuccala A. Progression of renal failure and hypertensive nephrosclerosis.


Kidney Int Suppl. 1998 Dec. 68:S55-9. [Medline].

35. Rostand SG, Brown G, Kirk KA, et al. Renal insufficiency in treated essential
hypertension. N Engl J Med. 1989 Mar 16. 320(11):684-8. [Medline].

36. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease. Review of clinical
and epidemiological evidence. Hypertension. 1989 May. 13(5 Suppl):I19-27. [Medline].

37. Toto RD, Mitchell HC, Smith RD, et al. "Strict" blood pressure control and progression
of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995 Sep. 48(3):851-9.
[Medline].

38. Hsu CY. Does non-malignant hypertension cause renal insufficiency? Evidence-based
perspective. Curr Opin Nephrol Hypertens. 2002 May. 11(3):267-72. [Medline].

39. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of
blood pressure in hypertensive participants of the hypertension optimal treatment (HOT)
study. J Am Soc Nephrol. 2001 Feb. 12(2):218-25. [Medline].

40. Cushman WC, Evans GW, Byington RP. Effects of intensive blood-pressure control in
type 2 diabetes mellitus. N Engl J Med. April. 17:1575-85. [Medline].

41. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D. Treatment of
hypertension in patients 80 years of age or older. N Engl J Med. 2008 May 1.
358(18):1887-98. [Medline].

42. Bhatnagar V, O'Connor DT, Brophy VH, et al. G-protein-coupled receptor kinase 4
polymorphisms and blood pressure response to metoprolol among African Americans:
sex-specificity and interactions. Am J Hypertens. 2009 Mar. 22(3):332-8. [Medline].
[Full Text].

43. Ruilope LM, Alcazar JM, Hernandez E, et al. Long-term influences of antihypertensive
therapy on microalbuminuria in essential hypertension. Kidney Int Suppl. 1994 Feb.
45:S171-3. [Medline].
44. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension:
significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999 Dec.
34(6):973-95. [Medline].

45. Kunz R, Wolbers M, Glass T, et al. The Cooperate trial: a letter of concern. Lancet. 2008
May 10. 371(9624):1575-6. [Medline].

46. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal
outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the
ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet.
2008 Aug 16. 372(9638):547-53. [Medline].

47. Collier DJ, Poulter NR, Dahlöf B, Sever PS, Wedel H, Buch J, et al. Impact of
amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens.
2011 Mar. 29(3):583-91. [Medline].

48. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus
amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med.
2008 Dec 4. 359(23):2417-28. [Medline].

49. Tomson CR, Petersen K, Heagerty AM. Does treated essential hypertension result in
renal impairment? A cohort study. J Hum Hypertens. 1991 Jun. 5(3):189-92. [Medline].

50. Rosansky SJ, Hoover DR, King L, et al. The association of blood pressure levels and
change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med.
1990 Oct. 150(10):2073-6. [Medline].

51. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in
men. N Engl J Med. 1996 Jan 4. 334(1):13-8. [Medline].

52. Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes
mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor
Intervention Trial. JAMA. 1997 Dec 17. 278(23):2069-74. [Medline].

53. Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive nephrosclerosis: the


nephrologist's view. Am J Kidney Dis. 1993 May. 21(5 Suppl 2):87-91. [Medline].